7XP Stock Overview
Develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Organon & Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.64 |
| 52 Week High | US$21.56 |
| 52 Week Low | US$10.15 |
| Beta | 0.81 |
| 11 Month Change | 0% |
| 3 Month Change | -2.23% |
| 1 Year Change | -9.91% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7XP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.6% | -1.2% |
| 1Y | -9.9% | -19.2% | 9.0% |
Return vs Industry: 7XP exceeded the German Pharmaceuticals industry which returned -19.5% over the past year.
Return vs Market: 7XP underperformed the German Market which returned 2.7% over the past year.
Price Volatility
| 7XP volatility | |
|---|---|
| 7XP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7XP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 7XP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 10,000 | Kevin Ali | www.organon.com |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
Organon & Co. Fundamentals Summary
| 7XP fundamental statistics | |
|---|---|
| Market cap | €4.90b |
| Earnings (TTM) | €957.80m |
| Revenue (TTM) | €5.81b |
5.1x
P/E Ratio0.8x
P/S RatioIs 7XP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7XP income statement (TTM) | |
|---|---|
| Revenue | US$6.35b |
| Cost of Revenue | US$2.60b |
| Gross Profit | US$3.75b |
| Other Expenses | US$2.70b |
| Earnings | US$1.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 06, 2024
| Earnings per share (EPS) | 4.07 |
| Gross Margin | 59.04% |
| Net Profit Margin | 16.50% |
| Debt/Equity Ratio | 18,154.2% |
How did 7XP perform over the long term?
See historical performance and comparison